Glucovance is a fixed-dose combination oral medication used to treat type 2 diabetes mellitus. It contains glipizide, a sulfonylurea that increases insulin secretion from pancreatic beta cells. It also contains metformin, which lowers hepatic glucose production and improves peripheral insulin sensitivity. The drug therefore acts by providing both an insulin stimulant and an insulin sensitizer in a single tablet. It helps control fasting and postprandial blood glucose levels without requiring separate prescriptions. The combined action reduces overall glycated hemoglobin concentrations over time. It does not replace insulin therapy and is used together with dietary measures and exercise.

Glucovance is a prescription drug formulated as a fixed dose combination of glipizide and metformin. It is indicated to improve glycemic control in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient. Glipizide stimulates pancreatic beta cells to release insulin by binding to atp sensitive potassium channels and closing them. Metformin reduces hepatic glucose output and enhances peripheral insulin sensitivity through activation of amp activated protein kinase. The additive action of increased insulin secretion and decreased hepatic gluconeogenesis leads to lower fasting and postprandial blood glucose levels. The medication is absorbed orally reaches peak plasma concentrations within one to three hours and is eliminated primarily renally with a half life of about five hours. Together the agents provide synergistic glycemic control without reliance on exogenous insulin administration.

The most common side effects often include headache mild nausea and occasional dizziness. Some people also report temporary fatigue or muscle aches that usually resolve without intervention. Gastrointestinal discomfort such as diarrhea or abdominal cramping can occur but is generally mild. Skin reactions like mild redness or itching are less frequent but have been documented. Rarely a sensation of lightheadedness may be experienced during the initial adjustment period. Most of these effects are short lived and tend to diminish as the body adapts. Individual variation influences how prominently these symptoms appear. Observing these patterns helps users understand typical responses without prompting medical action.

Headache is one of the most frequently reported side effects across many treatment approaches. Nausea tends to occur especially when the compound is taken on an empty stomach. Dizziness often accompanies sudden changes in dosage or timing. Dry mouth may develop as a result of reduced salivary secretion. Skin rash can appear in response to sensitivities to certain additives. Mild stomach upset is common when the formulation interacts with gastric lining. Temporary alteration of taste sensation sometimes follows ingestion.